Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study.
The Gambia Hepatitis Intervention Study (GHIS) was initiated by the International Agency for Research on Cancer (IARC) in 1986. It consisted of a randomized trial in the Gambian population, aiming to evaluate the protection provided by HBV vaccination administered during the first year of life against primary infection, the development of chronic carriage, and primary liver cancer. The results, reported at 9 years from the introduction of the vaccine as conferring a high degree of protection (83% against primary infection and 95% against chronic carriage), are briefly discussed. It is expected that HBV vaccination will result in a reduction of mortality from hepatocellular carcinoma, the most frequent cancer in males in sub-Sahara Africa.
International Agency for Research on Cancer, Lyon, France. montesano@iarc.fr
Ruggero
R
Montesano
D000293:Adolescent; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005714:Gambia; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007231:Infant, Newborn; D008113:Liver Neoplasms / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D017325:Hepatitis B Vaccines